IDH-mutant and 1p/19q-codeleted oligodendroglioma

This study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…

This study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiat…

This early-stage trial tests whether combining vorasidenib (a targeted therapy) with lomustine (a chemotherapy) is safe for people with recurrent IDH-mutant gliomas, a type of brain cancer. About 24 adults whose tumors have returned will receive different doses to find the best o…

This phase 2 trial tests a single dose of FG001, a fluorescent dye, in 76 adults with newly diagnosed high-grade glioma. The dye is given before surgery and glows under a special light, helping surgeons tell tumor from healthy tissue during removal. The study checks how well the …